the benefit–risk assessment for COVID-19 (mRNA) vaccination underscores a very strong favourable balance for all age and sex groups
Despite these rare cases of self-limited myocarditis, the benefit–risk assessment for COVID-19 (mRNA) vaccination underscores a very strong favourable balance for all age and sex groups. Vaccines against COVID-19 have proved to be highly effective at preventing symptomatic disease in clinical trials and real-world reports. Vaccination flattens the epidemiology curve and strongly reduces the risk of COVID-19-related hospitalization, intensive care admission and death in both young and elderly individuals10. COVID-19 vaccination also reduces the risk of COVID-19-associated acute kidney injury, arrhythmia and thrombosis10. Moreover, with COVID-19 vaccination, the risk of myocardial injury and myocarditis decreases 1,000-fold in the general population, with a minor 1–5-fold increased risk of mild myocarditis in young adults. Therefore, COVID-19 vaccination has an extremely favourable risk ratio for myocarditis and should be recommended in adolescent and adult populations